Your browser doesn't support javascript.
loading
The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma.
Hao, Dapeng; Han, Guangchun; Sinjab, Ansam; Gomez-Bolanos, Lorena Isabel; Lazcano, Rossana; Serrano, Alejandra; Hernandez, Sharia D; Dai, Enyu; Cao, Xuanye; Hu, Jian; Dang, Minghao; Wang, Ruiping; Chu, Yanshuo; Song, Xingzhi; Zhang, Jianhua; Parra, Edwin R; Wargo, Jennifer A; Swisher, Stephen G; Cascone, Tina; Sepesi, Boris; Futreal, Andrew P; Li, Mingyao; Dubinett, Steven M; Fujimoto, Junya; Solis Soto, Luisa M; Wistuba, Ignacio I; Stevenson, Christopher S; Spira, Avrum; Shalapour, Shabnam; Kadara, Humam; Wang, Linghua.
Affiliation
  • Hao D; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sinjab A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gomez-Bolanos LI; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Serrano A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hernandez SD; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dai E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cao X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hu J; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Dang M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wargo JA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Swisher SG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cascone T; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sepesi B; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Futreal AP; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dubinett SM; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Fujimoto J; Department of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Solis Soto LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Stevenson CS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Spira A; Lung Cancer Initiative at Johnson & Johnson, Boston, Massachusetts.
  • Shalapour S; Lung Cancer Initiative at Johnson & Johnson, Boston, Massachusetts.
  • Kadara H; Section of Computational Biomedicine, Boston University, Boston, Massachusetts.
  • Wang L; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discov ; 12(11): 2626-2645, 2022 11 02.
Article in En | MEDLINE | ID: mdl-36098652
ABSTRACT
Tumor-infiltrating B and plasma cells (TIB) are prevalent in lung adenocarcinoma (LUAD); however, they are poorly characterized. We performed paired single-cell RNA and B-cell receptor (BCR) sequencing of 16 early-stage LUADs and 47 matching multiregion normal tissues. By integrative analysis of ∼50,000 TIBs, we define 12 TIB subsets in the LUAD and adjacent normal ecosystems and demonstrate extensive remodeling of TIBs in LUADs. Memory B cells and plasma cells (PC) were highly enriched in tumor tissues with more differentiated states and increased frequencies of somatic hypermutation. Smokers exhibited markedly elevated PCs and PCs with distinct differentiation trajectories. BCR clonotype diversity increased but clonality decreased in LUADs, smokers, and with increasing pathologic stage. TIBs were mostly localized within CXCL13+ lymphoid aggregates, and immune cell sources of CXCL13 production evolved with LUAD progression and included elevated fractions of CD4 regulatory T cells. This study provides a spatial landscape of TIBs in early-stage LUAD.

SIGNIFICANCE:

While TIBs are highly enriched in LUADs, they are poorly characterized. This study provides a much-needed understanding of the transcriptional, clonotypic states and phenotypes of TIBs, unraveling their potential roles in the immunopathology of early-stage LUADs and constituting a road map for the development of TIB-targeted immunotherapies for the treatment of this morbid malignancy. This article is highlighted in the In This Issue feature, p. 2483.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Discov Year: 2022 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Discov Year: 2022 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA